Mustafa T Ardah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5699876/publications.pdf

Version: 2024-02-01

24 papers	1,215 citations	516215 16 h-index	676716 22 g-index
24 all docs	24 docs citations	24 times ranked	2001 citing authors

#	Article	IF	Citations
1	Î±-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2109617119.	3.3	60
2	Dose-related biphasic effect of the Parkinsonâ€™s disease neurotoxin MPTP, on the spread, accumulation, and toxicity of Î±-synuclein. NeuroToxicology, 2021, 84, 41-52.	1.4	12
3	Ellagic Acid Prevents Î±-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated Î±-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy. International Journal of Molecular Sciences, 2021, 22, 13398.	1.8	7
4	Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 1519.	1.8	34
5	Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. BMC Complementary Medicine and Therapies, 2020, 20, 73.	1.2	22
6	Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Translational Neurodegeneration, 2019, 8, 18.	3.6	48
7	Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates Î±-synuclein aggregation in vitro. Neurochemistry International, 2019, 128, 115-126.	1.9	33
8	Saturated fatty acid regulated lncRNA dataset during in vitro human embryonic neurogenesis. Data in Brief, 2018, 21, 1061-1065.	0.5	1
9	Saturated fatty acid alters embryonic cortical neurogenesis through modulation of gene expression in neural stem cells. Journal of Nutritional Biochemistry, 2018, 62, 230-246.	1.9	11
10	Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated Î±-Synuclein Mutant A53T and Affects Locomotor Activity. Frontiers in Neuroscience, 2018, 12, 81.	1.4	28
11	Biochemical and Functional Characterization of Mouse Mammary Tumor Virus Full-Length Pr77Gag Expressed in Prokaryotic and Eukaryotic Cells. Viruses, 2018, 10, 334.	1.5	13
12	Neuroprotective potential of Thymoquinone in MPTP Model of Parkinson's Disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-129.	0.0	0
13	ATP13A2 Gene silencing in Drosophila affects autophagic degradation of A53T mutant alpha-synuclein. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR5-5.	0.0	0
14	Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Scientific Reports, 2017, 7, 16533.	1.6	110
15	Higher O-GlcNAc Levels Are Associated with Defects in Progenitor Proliferation and Premature Neuronal Differentiation during in-Vitro Human Embryonic Cortical Neurogenesis. Frontiers in Cellular Neuroscience, 2017, 11, 415.	1.8	24
16	Effects of Aminoglycoside Antibiotics on Human Embryonic Stem Cell Viability during Differentiation In Vitro. Stem Cells International, 2017, 2017, 1-18.	1.2	11
17	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	4.4	39
18	Longitudinal changes in CSF alphaâ€synuclein species reflect Parkinson's disease progression. Movement Disorders, 2016, 31, 1535-1542.	2.2	120

#	Article	IF	Citations
19	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinsonâ€™s disease. Molecular Neurodegeneration, 2016, 11, 7.	4.4	198
20	Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. Molecular Therapy, 2016, 24, 746-758.	3.7	38
21	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. Neurobiology of Disease, 2015, 79, 81-99.	2.1	116
22	Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiology of Disease, 2015, 74, 89-101.	2.1	90
23	Structure activity relationship of phenolic acid inhibitors of ÃŽÂ±-synuclein fibril formation and toxicity. Frontiers in Aging Neuroscience, 2014, 6, 197.	1.7	103
24	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiology of Disease, 2014, 63, 1-11.	2.1	97